Uveitis Therapeutics Pipeline to Witness Numerous Technological Advancements in the Coming Years     |    Candidiasis Therapeutics Pipeline to Witness Many Technological Advancements in Future     |    Global Virtual Power Plant Market to Reach 32.4GW by 2023

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

Chronic Obstructive Pulmonary Disease Therapeutics Pipeline to Witness Huge Collaborations in Near Future

Chronic Obstructive Pulmonary Disease Therapeutics Pipeline to Witness Huge Collaborations in Near Future

May 2017

According to a new research report “Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Chronic obstructive pulmonary disease currently exhibits a pipeline with 65 drug candidates.

Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

Chronic obstructive pulmonary disease pipeline in 2017

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates, of which eight drug candidates are in Phase III stage of development, 24 drug candidates are in Phase II stage, nine drug candidates are in Phase I, 22 drug candidates are in Pre-Clinical stage and two drug candidates are in Discovery stage. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. In this condition, lung cells lose their elasticity and get enlarged, which leads to reduction in the amount of gas exchange in the lungs. Sometimes, it progresses to form cancer, stroke and coronary artery disease.

Insights on pipeline segments

As per the findings of the research, around 40.0% of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route, 12.0% are being developed to be administered by oral route, 5.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by intravenous route, 3.0% are being developed to be administered by another route and 37.0% are being developed to be administered by other routes that are undisclosed.

Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development

MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of CNTO6785 for the treatment of chronic obstructive pulmonary disease. The technology platform is used for the in vitro generation of highly specific and fully human antibodies. HuCAL antibodies are produced in bacteria, and the technology enables in vitro selection to isolate antibodies with the desired characteristics. HuCAL is generated by de novo gene synthesis, and the large library is screened with a technique called phage display, to identify the antibody with a high affinity to the investigated antigen.

Major companies collaborate for the development of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline

Many companies are involved in the development of drugs for the chronic obstructive pulmonary disease therapeutics pipeline, with their products in different phases. Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc and AstraZeneca plc have their drug candidates in the Phase III stage of development. Adamis Pharmaceuticals Corporation has two drug candidates in Phase II stage of development. Novartis AG also has two drug candidates in Phase II stage of development. Glenmark Pharmaceuticals Ltd. has two drug candidates in Pre-Clinical stage of development.

The research also found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. entered into an agreement with AstraZeneca plc for the exclusive rights of benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease in Asia. In June 2013, AstraZeneca plc acquired Pearl Therapeutics, Inc., which was involved in the development of inhaled small-molecule therapeutics for respiratory disease.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation, Chiesi Farmaceutici S.p.A., Cytokinetics, Inc., Novartis AG and Theravance Biopharma R & D, Inc.

Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis

  • By Phase
    • Phase III
    • Phase II
    • Phase I
    • Pre-Clinical
    • Discovery

Note: In the pipeline analysis, inactive and discontinued products have been excluded.

  • By Route of Administration
    • Inhalation
    • Oral
    • Intravenous
    • Subcutaneous
    • Not Disclosed
    • Others
  • By Molecule Type
    • Small Molecule
    • Monoclonal Antibody
    • Peptides
    • Others
  • By Company

LATEST PUBLICATIONS BY P&S

  • Marketing Automation Software Market

    P&S Market Research - Marketing Automation Software Market report Market Overview Marketing automation software refers to a software platform designed for the marketers and marketing d... Continue Reading
  • Synovial Sarcoma Therapeutics Pipeline Analysis, 2017

    P&S Market Research - Synovial Sarcoma Therapeutics Pipeline Analysis report Disease Overview Synovial sarcoma is rare type of cancer and approximately one to three people in every million people... Continue Reading
  • Candidiasis Therapeutics Pipeline Analysis, 2017

    P&S Market Research - Candidiasis Therapeutics Pipeline Analysis report Disease Overview Candidiasis is a very common type of fungal infection caused by fungus known as candida. Candida is u... Continue Reading
  • Uveitis Therapeutics Pipeline Analysis, 2017

    P&S Market Research - Uveitis Therapeutics Pipeline Analysis report Disease Overview Uveitis is a chronic inflammatory disease which causes swelling and pain in eye tissues, mainly uvea.... Continue Reading
  • Smart Homes Market

    P&S Market Research - Smart Homes Market report Market Overview Smart homes refer to smart buildings, usually the new ones that are equipped with special electronic f... Continue Reading

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Address : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment